Asia Pacific Carrier Screening Market By Technology, By End user, By Country, Opportunity Analysis and Industry Forecast, 2021 - 2027

The Asia Pacific Carrier Screening Market is expected to witness market growth of 12.58% CAGR during the forecast period (2021-2027).

The chances to cure and effectively manage a disease is expected to grow manifold if it is diagnosed early. Treatment of the disease early may help the patient to accommodate it in a better way. Early disease detection assists individuals plan ahead, while they are still able to take valuable decisions in terms of their health and bolsters requirements and on financial and legal matters. Genetic disorders like sickle cell anemia, cystic fibrosis, and Tay-Sachs disease, are inherited disorders that are deadly in nature. However, carrier screening for these fatal diseases can offer valuable data regarding a couple’s possibility of having a child with a genetic disorder.

There is a growing demand for different diagnosis methods like carrier screening in developing countries like India, Japan, and China. This surging demand for wearables is expected to bolster the growth of the regional carrier screening market in the upcoming years. In addition, the rising cases of people suffering from different diseases will also positively impact the growth of the market in this region.

The Asia Pacific is witnessing high consumer awareness regarding their health and a surge in the number of chronic diseases. This is expected to act as a major catalyst for the growth of the regional carrier screening market. Moreover, players operating in this region are constantly developing different kinds of products to explore the genetic errors in the human body that is expected to help the people to prevent the chances of transmission of the defected genes to their offspring. These factors are expected to open new growth avenues for the players operating in the regional carrier screening market during the forecasting period.

The China market dominated the Asia Pacific Carrier Screening Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $158.2 million by 2027. The Japan market is poised to grow a CAGR of 13.9% during (2021 - 2027). Additionally, The India market is anticipated to grow a CAGR of 14% during (2021 - 2027).

Based on Technology, the market is segmented into DNA Sequencing, Microarrays, Polymerase Chain Reaction and Other technology. Based on End user, the market is segmented into Hospital and Clinics, Physician Offices, Reference Laboratories and Other End Users. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Quest Diagnostics, Incorporated, Thermo Fisher Scientific, Illumina, Inc., Eurofins Scientific Group, Invitae Corporation, OPKO Health, Inc., Fulgent Genetics, Sema4 OpCo, Inc., Myriad Genetics, Inc., and Natera, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Type

• Expanded Carrier Screening and
• Targeted Disease Carrier Screening

By Technology

• DNA Sequencing
• Microarrays
• Polymerase Chain Reaction and
• Other technology

By End User

• Hospital and Clinics
• Physician Offices
• Reference Laboratories and
• Other End Users

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Quest Diagnostics, Incorporated
• Thermo Fisher Scientific
• Illumina, Inc.
• Eurofins Scientific Group
• Invitae Corporation
• OPKO Health, Inc.
• Fulgent Genetics
• Sema4 OpCo, Inc.
• Myriad Genetics, Inc.
• Natera, Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free